Zydus Cadila has received the final approval from the USFDA to market Allopurinol Tablets USP, 100 mg and 300 mg. The drug is indicated in the management of patients with gout and patients with cancer who are receiving therapy that causes elevations of serum and urinary uric acid levels. It will be manufactured at the group’s formulations manufacturing facility at Baddi.
 
The sales of Allopurinol Tablets USP are estimated at USD 141.2 million. The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 4.3, or 0.86%, to trade at Rs 505.70. The total volume of shares traded was 5,440 at the BSE (9.46 a.m., Monday).